

## Supplementary Online Content

Zash R, Jacobson DL, Diseko M, et al. Comparative safety of antiretroviral treatment regimens in pregnancy. *JAMA Pediatr*. Published online August 7, 2017. doi:10.1001/jamapediatrics.2017.2222

### **eTable.** Additional Analyses

This supplementary material has been provided by the authors to give readers additional information about their work.

**eTable. Additional Analyses**

	<b>TDF/FTC/ EFV aRR (95% CI)</b>	<b>TDF/FTC/ NVP aRR (95% CI)</b>	<b>ZDV/3TC/ NVP aRR (95% CI)</b>	<b>TDF/FTC/ LPV-r aRR (95% CI)</b>	<b>ZDV/3TC/ LPV-r aRR (95% CI)</b>
<b>Restricted to CD4 &gt;350 in pregnancy</b>					
<b>Any Adverse Outcome</b>	1 [Reference]	1.0 (0.8-0.3)	1.3 (1.1-1.6)	1.2 (0.9-1.7)	1.2 (0.8-1.8)
<b>Any Severe Adverse Outcome</b>	1 [Reference]	1.3 (0.9-2.0)	2.4 (1.0-2.0)	1.6 (0.9-2.9)	2.7 (1.5-4.8)
<b>Preterm (&lt;37wks)</b>	1 [Reference]	0.5 (0.3-0.8)	0.9 (0.7-1.2)	1.4 (0.9-2.2)	0.8 (0.4-1.6)
<b>Very Preterm (&lt;32wks)</b>	1 [Reference]	0.9 (0.4-2.2)	1.1 (0.6-2.2)	1.8 (0.6-5.2)	1.3 (0.3-5.6)
<b>Small for gestational age (SGA) (&lt;10<sup>th</sup>%tile)</b>	1 [Reference]	1.7 (1.2-2.3)	1.8 (1.3-2.4)	1.4 (0.8-2.3)	1.8 (1.1-3.2)
<b>Very SGA (&lt;3<sup>rd</sup> %tile)</b>	1 [Reference]	1.6 (0.9-2.7)	1.5 (0.9-2.4)	2.0 (1.0-4.1)	2.6 (1.2-5.8)
<b>Stillbirth</b>	*				
<b>Neonatal Death</b>	*				
<b>Adjusted for CD4 count</b>					
<i>Any Adverse Outcome</i>					
<b>Model excluding unknown CD4</b>	1 [Reference]	1.1 (0.9-1.3)	1.3 (1.1-1.5)	1.2 (0.9-1.6)	1.1 (0.8-1.7)
<b>Additionally adjusting for CD4 (continuous)</b>	1 [Reference]	1.1 (0.9-1.3)	1.3 (1.1-1.5)	1.3 (1.0-1.7)	1.2 (0.8-1.7)
<b>Additionally adjusting for CD4 (categorical)</b>	1 [Reference]	1.1 (0.9-1.3)	1.3 (1.1-1.5)	1.2 (0.9-1.7)	1.2 (0.8-1.7)
<i>Any Severe Adverse Outcome</i>					
<b>Model excluding unknown CD4</b>	1 [Reference]	1.4 (0.9-2.0)	1.4 (1.0-2.0)	1.6 (0.9-2.8)	2.4 (1.4-4.2)

	TDF/FTC/ EFV aRR (95% CI)	TDF/FTC/ NVP aRR (95% CI)	ZDV/3TC/ NVP aRR (95% CI)	TDF/FTC/ LPV-r aRR (95% CI)	ZDV/3TC/ LPV-r aRR (95% CI)
<b>Any Severe Adverse Outcome (cont.)</b>					
<b>Additionally adjusting for CD4 (continuous)</b>	1 [Reference]	1.4 (1.0-2.1)	1.5 (1.0-2.0)	1.8 (1.0-3.1)	2.6 (1.5-4.5)
<b>Additionally adjusting for CD4 (categorical)</b>	1 [Reference]	1.4 (1.0-2.1)	1.5 (1.1-2.0)	1.7 (1.0-2.9)	2.4 (1.4-4.2)
<b>Adjusted for time on ART prior to conception (days)</b>					
<b>Any Adverse Outcome</b>	1 [Reference]	1.1 (1.0-1.3)	1.3 (1.2-1.5)	1.3 (1.1-1.5)	1.2 (1.0-1.5)
<b>Any Severe Adverse Outcome</b>	1 [Reference]	1.4 (1.2-1.8)	1.7 (1.4-2.0)	1.5 (1.1-2.1)	1.9 (1.4-2.6)
<b>Adjusted for time on ART prior to conception (categorical: &lt;2yrs- 2-5yrs- &gt;5yrs)</b>					
<b>Any Adverse Outcome</b>	1 [Reference]	1.1 (1.0-1.3)	1.3 (1.2-1.4)	1.3 (1.1-1.5)	1.2 (1.0-1.5)
<b>Any Severe Adverse Outcome</b>	1 [Reference]	1.4 (1.1-1.7)	1.6 (1.3-2.0)	1.4 (1.0-2.0)	1.8 (1.3-2.5)
<b>Adjusted for calendar year of delivery</b>					
<b>Any Adverse Outcome</b>	1 [Reference]	1.1 (1.0-1.3)	1.3 (1.2-1.4)	1.3 (1.1-1.5)	1.2 (1.0-1.5)
<b>Any Severe Adverse Outcome</b>	1 [Reference]	1.4 (1.2-1.8)	1.7 (1.5-2.0)	1.6 (1.2-2.1)	1.9 (1.4-2.6)
<b>Re-categorized all unspecified ART started after Jan 1, 2012 as TDF/FTC/EFV</b>					
<b>Any Adverse Outcome</b>	1 [Reference]	1.1 (1.0-1.2)	1.3 (1.2-1.4)	1.3 (1.1-1.5)	1.2 (1.0-1.4)
<b>Any Severe Adverse Outcome</b>	1 [Reference]	1.3 (1.1-1.6)	1.5 (1.3-1.8)	1.4 (1.1-1.9)	1.8 (1.3-2.4)

	TDF/FTC/ EFV aRR (95% CI)	TDF/FTC/ NVP aRR (95% CI)	ZDV/3TC/ NVP aRR (95% CI)	TDF/FTC/ LPV-r aRR (95% CI)	ZDV/3TC/ LPV-r aRR (95% CI)
<b>Included all births to women who were on ART at conception but changed or terminated ART (using conception regimen)</b>					
Any Adverse Outcome	1 [Reference]	1.1 (1.0-1.3)	1.3 (1.2-1.4)	1.3 (1.1-1.5)	1.2 (1.0-1.5)
Any Severe Adverse Outcome	1 [Reference]	1.4 (1.2-1.7)	1.7 (1.4-2.0)	1.6 (1.2-2.1)	1.9 (1.4-2.6)
<b>Adjusted models including the robust variance estimator for clustering by maternity site</b>					
Any Adverse Outcome	1 [Reference]	1.1 (1.0-1.3)	1.3 (1.2-1.4)	1.3 (1.2-1.4)	1.2 (1.0-1.5)
Any Severe Adverse Outcome	1 [Reference]	1.4 (1.2-1.6)	1.7 (1.5-1.9)	1.6 (1.4-1.8)	1.9 (1.7-2.2)
<b>Excluded Neonatal Death from the primary composite outcomes</b>					
Any Adverse Outcome	1 [Reference]	1.1 (1.0-1.3)	1.3 (1.2-1.4)	1.3 (1.1-1.5)	1.2 (1.0-1.4)
Any Severe Adverse Outcome	1 [Reference]	1.4 (1.2-1.7)	1.7 (1.4-2.0)	1.6 (1.2-2.2)	1.8 (1.3-2.5)
<b>Excluded SGA if gestational age &gt;39wks</b>					
SGA (<10 <sup>th</sup> %tile)	1 [Reference]	1.7 (1.4-2.1)	2.0 (1.7-2.4)	1.7 (1.2-2.3)	1.2 (0.8-1.9)
<b>Low Birthweight (LBW)</b>					
LBW <2500g	1 [Reference]	1.3 (1.1-1.5)	1.6 (1.5-1.9)	1.4 (1.1-1.8)	1.6 (1.2-2.1)
Very LBW <1500g	1 [Reference]	1.6 (1.1-2.5)	2.2 (1.6-3.0)	1.6 (0.8-3.1)	2.2 (1.2-4.3)
<b>Time on ART prior to conception as the exposure (adjusting for ART regimen)</b>	<b>&lt;2years aRR (95% CI)</b>	<b>2-4 years aRR (95% CI)</b>	<b>5-10 years aRR (95% CI)</b>	<b>&gt;10 years aRR (95% CI)</b>	
Any Adverse Outcome	1 [Reference]	0.9 (0.8-1.1)	1.0 (0.8-1.1)	0.9 (0.7-1.0)	
Any Severe Adverse Outcome	1 [Reference]	0.9 (0.7-1.2)	0.9 (0.7-1.2)	0.8 (0.6-1.1)	

\* Due to low number of outcomes, models do not converge.